The Digital Medicine Society (DiMe) announced today a new collaboration with Acclinate, Amgen, GSK, Lightship, Medable, Rubix LS, Sage Bionetworks, Savvy Cooperative, and THREAD Research to drive inclusion in digital clinical trials. The initiative aims to provide the tools and framework necessary to successfully integrate diverse perspectives during the planning process for trials that include a technology device for participation.
Key Takeaways and Learnings Recent clinical research recommendations reinforce the need for robust and sustained community engagement. The FDA’s recen...
Key Takeaways and Learnings Clinical trials fall short when communities of color are underrepresented. Trust and awareness are longstanding obstacles ...
Key Takeaways and Learnings Many historically marginalized communities continue to be excluded from clinical trials. Traditional clinical recruitment ...
The past few years have laid bare many disparities in U.S. healthcare.On average, Black Americans live fewer years than white Americans— commonly due ...
There are few people as seemingly healthy as Olympic gold medalists. But when sprinter Tori Bowie died in her home due to complications from childbirt...
From the content of Diversity Action Plans to the nuances of submission, implementation, and monitoring for inclusive and representative research, the...
Though the life sciences industry has committed to improving diversity in clinical trials, there’s still work to be done. Childhood asthma is a case i...
Earlier this year, the U.S. Food and Drug Administration updated its guidance document on collecting race and ethnicity data in clinical trials. The d...
Under 2022’s Food and Drug Omnibus Reform Act, clinical trial sponsors are required tosubmit diversity action plans with pivotal drug studies such as ...
